Combinations are the Future in FLT3-Mutated AML

Jessica K. Altman, MD, and Naval G. Daver, MD, share their approaches to genetic testing for FLT3 and other actionable mutations in acute myeloid leukemia (AML).

Insight regarding the assessment of the prevalence of FLT3-ITD versus FLT3-TKD mutations and allelic burden in newly diagnosed acute myeloid leukemia.

Leukemia experts discuss the role of genetic testing to check for FLT3 mutations at the time of relapse in acute myeloid leukemia.

Jessica K. Altman, MD, reviews the safety and efficacy of gilteritinib as seen in the ADMIRAL trial for the treatment of relapsed/refractory acute myeloid leukemia.

Experts in leukemia comment on the utilization of FLT3 inhibitors in combination with chemotherapy in early and recurrent acute myeloid leukemia.

Naval G. Daver, MD, reviews the safety and efficacy of quizartinib in relapsed/refractory acute myeloid leukemia as seen in the phase 3 QuANTUM-R study.

Examining the need to achieve a true CR (complete remission), especially with recent targeted therapies in relapsed/refractory acute myeloid leukemia.

Naval G. Daver, MD, leads the discussion on the use sorafenib in combination with hypomethylating agents (HMA) for the treatment of relapsed FLT3-mutated AML.

Jessica K. Altman, MD, and Naval G. Daver, MD, discuss what is known in terms of mechanisms of resistance to FLT3 inhibitors used to treat acute myeloid leukemia.

Experts in hematology comment on when it’s appropriate to use gilteritinib, particularly as a combination therapy, to treat patients with FLT3-mutated acute myeloid leukemia.

A discussion on the use of venetoclax combinations with FLT3 inhibitors, especially in older patients with FLT3-mutated acute myeloid leukemia.

Jessica K. Altman, MD, and Naval G. Daver, MD, review novel combinations under investigation for the treatment of FLT3-mutated acute myeloid leukemia.